Sun Pharma's research arm Sun Pharma Advanced Research Company (SPARC) Monday announced top-line results of the pivotal BE study for its Paclitaxel injection concentrate for suspension (PICS) which has been found to be a bioequivalent to Abraxane, used to treat metastatic breast cancer.
Paclitaxel injection concentrate for suspension (PICS) is a novel formulation of Paclitaxel developed using SPARC's proprietary Nanotecton technology.
The company said it is targeting a new drug application with the US health regulator in the next few months.
"Pivotal bioequivalence (BE) ," SPARC said in a regulatory fling.
SPARC CEO Anil Raghavan said overall US Paclitaxel market is estimated to be about USD 700 million (IQVIA MAT Sep 2018). The current market is dominated by Cremophor-based Paclitaxel formulations, which accounts for 70 per cent of unit sales.
"With launch of novel formulations, market for nano-formulations of Paclitaxel is expected to grow," he added.
Shares of SPARC were trading 2.15 per cent at Rs 278.05 apiece on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)